AU2015289504B2 - Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent - Google Patents

Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent Download PDF

Info

Publication number
AU2015289504B2
AU2015289504B2 AU2015289504A AU2015289504A AU2015289504B2 AU 2015289504 B2 AU2015289504 B2 AU 2015289504B2 AU 2015289504 A AU2015289504 A AU 2015289504A AU 2015289504 A AU2015289504 A AU 2015289504A AU 2015289504 B2 AU2015289504 B2 AU 2015289504B2
Authority
AU
Australia
Prior art keywords
radiation
cerium oxide
effective dose
therapeutically effective
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015289504A
Other languages
English (en)
Other versions
AU2015289504A1 (en
Inventor
Cheryl BAKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocurity Pharmaceuticals Inc
Original Assignee
Biocurity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocurity Pharmaceuticals Inc filed Critical Biocurity Pharmaceuticals Inc
Publication of AU2015289504A1 publication Critical patent/AU2015289504A1/en
Assigned to BioCurity Pharmaceuticals Inc. reassignment BioCurity Pharmaceuticals Inc. Amend patent request/document other than specification (104) Assignors: BIOCURITY HOLDINGS, INC.
Application granted granted Critical
Publication of AU2015289504B2 publication Critical patent/AU2015289504B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2015289504A 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent Ceased AU2015289504B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Publications (2)

Publication Number Publication Date
AU2015289504A1 AU2015289504A1 (en) 2017-02-23
AU2015289504B2 true AU2015289504B2 (en) 2020-12-17

Family

ID=55079076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015289504A Ceased AU2015289504B2 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Country Status (9)

Country Link
EP (2) EP3169312B1 (https=)
JP (2) JP6706255B2 (https=)
CN (2) CN106604719B (https=)
AU (1) AU2015289504B2 (https=)
BR (1) BR112017000800A8 (https=)
CA (1) CA2955384C (https=)
MX (1) MX387363B (https=)
RU (2) RU2704811C2 (https=)
WO (1) WO2016011328A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN111093373A (zh) * 2017-04-12 2020-05-01 V·J·班格万丁 组合物、包装的药物和使用泊沙康唑用于敏化抗性肿瘤的方法
CA3060407A1 (en) * 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
MX2021003710A (es) * 2018-09-28 2021-08-19 Univ Colorado Regents Metodos para prevenir y tratar inflamacion y fibrosis pulmonar.
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
CA3181177A1 (en) * 2020-04-30 2021-10-04 University Of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
JP2024531479A (ja) 2021-08-27 2024-08-29 アセンタウィッツ ファーマシューティカルズ リミテッド 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
US20250295677A1 (en) 2022-04-15 2025-09-25 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
TW202434258A (zh) 2023-02-27 2024-09-01 大陸商深圳艾欣達偉醫藥科技有限公司 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法
AU2024317010A1 (en) 2023-07-28 2026-02-26 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093931A9 (en) * 2005-04-29 2012-04-19 Mcginnis James F Inhibition of Neovascularization by Cerium Oxide Nanoparticles
US20120282185A1 (en) * 2009-12-09 2012-11-08 Isis Innovation Limited Particles for the treatment of cancer in combination with radiotherapy
WO2015164780A1 (en) * 2014-04-25 2015-10-29 The Regents Of The University Of Michigan Nanoparticle therapy in cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP1904072A4 (en) * 2005-06-27 2009-06-17 Edward Via Virginia College Of ANTI-INFLAMMATORY, RADIOPROTECTIVE CERTIFICATE OXIDE NANOPARTICLE CAPACITIES AND ENHANCING LONGEVITY
WO2009086416A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
US9393439B2 (en) * 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
EP2841055A4 (en) * 2012-04-04 2015-09-16 Univ Duke METHOD OF USE OF CERIUM OXIDE NANOPARTICLES TO REDUCE OR PROTECT FROM RADIATION DAMAGE
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093931A9 (en) * 2005-04-29 2012-04-19 Mcginnis James F Inhibition of Neovascularization by Cerium Oxide Nanoparticles
US20120282185A1 (en) * 2009-12-09 2012-11-08 Isis Innovation Limited Particles for the treatment of cancer in combination with radiotherapy
WO2015164780A1 (en) * 2014-04-25 2015-10-29 The Regents Of The University Of Michigan Nanoparticle therapy in cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. SACK ET AL, "Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles--A Novel Aspect in Cancer Therapy", MOLECULAR CANCER THERAPEUTICS, 2014, vol. 13, no. 7, pages 1740-1749 *
YING GAO ET AL, "Cerium oxide nanoparticles in cancer", ONCOTARGETS AND THERAPY, (2014-05-01), doi:10.2147/OTT.S62057, page 835 *
ZHANG LI ET AL, "Selective cytotoxicity effect of cerium oxide nanoparticles under UV irradiation", JOURNAL OF BIOMEDICAL NANOTECHNO, AMERICAN SCIENTIFIC PUBLISHERS, US, (2014-01-01), vol. 10, no. 2, ISSN 1550-7033, pages 278 - 286 *

Also Published As

Publication number Publication date
EP3169312B1 (en) 2020-09-02
EP3169312A4 (en) 2017-12-27
RU2019133284A (ru) 2019-12-05
JP6706255B2 (ja) 2020-06-03
JP2017521499A (ja) 2017-08-03
MX387363B (es) 2025-03-18
CN111184733A (zh) 2020-05-22
CA2955384C (en) 2024-03-12
AU2015289504A1 (en) 2017-02-23
RU2704811C2 (ru) 2019-10-31
RU2017104909A (ru) 2018-08-17
MX2017000578A (es) 2017-07-20
CN106604719B (zh) 2019-11-26
BR112017000800A2 (pt) 2018-07-03
EP3628308A1 (en) 2020-04-01
CA2955384A1 (en) 2016-01-21
CN106604719A (zh) 2017-04-26
RU2017104909A3 (https=) 2019-01-28
BR112017000800A8 (pt) 2023-04-25
JP2020158507A (ja) 2020-10-01
WO2016011328A1 (en) 2016-01-21
EP3169312A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
AU2015289504B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
Zhu et al. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Linch et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
KR102456088B1 (ko) 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
RU2754452C2 (ru) Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
Ding et al. SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
HK40026959A (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
HK1237267B (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
HK1237267A1 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Dębska-Szmich et al. Clinical use of cyclin-dependent kinase (CDK) 4/6 inhibitors in patients with breast cancer—literature review
김유석 Anti-tumor Effects of the Tyrosine Kinase Inhibitor Rivoceranib in Canine Melanoma and Mammary Gland Tumor
Cazzanelli et al. Colorectal Cancer Therapeutic Approaches: From Classical Drugs to New Nanoparticles
Auricchio et al. VAL 201–An Inhibitor of Androgen Receptor-associated Src and a Potential Treatment of Castration-resistant Prostate Cancer
WO2025181652A1 (en) Treatment of cancer using aripiprazole and anticancer agent
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
KR20220140723A (ko) 암의 치료를 위한 약제학적 조합
Johnson New antiangiogenic compounds and strategies for their clinical development
Licitra et al. Multikinase inhibitors in thyroid cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BIOCURITY PHARMACEUTICALS INC.

Free format text: FORMER NAME(S): BIOCURITY HOLDINGS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired